Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of “Reduce” from Analysts

Moderna, Inc. (NASDAQ:MRNA) has received a consensus rating of “Reduce” from the eighteen brokerages that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $28.7692.

MRNA has been the subject of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Monday, October 20th. Citigroup restated a “neutral” rating on shares of Moderna in a research report on Monday, January 19th. BMO Capital Markets upgraded Moderna from a “market perform” rating to a “buy” rating in a research report on Monday, January 12th. Wolfe Research reissued an “underperform” rating and set a $17.00 price objective on shares of Moderna in a report on Thursday, November 20th. Finally, Wall Street Zen upgraded shares of Moderna from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th.

Moderna Stock Performance

NASDAQ:MRNA opened at $42.23 on Wednesday. Moderna has a 52-week low of $22.28 and a 52-week high of $55.20. The business’s fifty day moving average is $37.26 and its 200 day moving average is $29.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29. The firm has a market cap of $16.50 billion, a price-to-earnings ratio of -5.81 and a beta of 1.31.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.79) by $0.68. The firm had revenue of $678.00 million for the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The company’s revenue for the quarter was down 33.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.91) earnings per share. Research analysts predict that Moderna will post -9.61 EPS for the current year.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Q4 results beat expectations: Moderna reported a narrower-than-expected loss (GAAP EPS -$2.11) and revenue above estimates, driven by stronger COVID-19 vaccine sales; management reiterated a ~10% revenue growth target for 2026, pushing near-term sentiment. Moderna beats fourth-quarter revenue estimates
• Positive Sentiment: Unusually large bullish options flow: Traders bought about 146,946 call contracts Friday (≈75% above typical call volume), signalling outsized short-term bullish positioning that can amplify upside moves if momentum continues.
• Neutral Sentiment: Technical picture is mixed but showing early bull signals: Several technical analysts point to support holding after a sharp YTD rally and highlight possible breakout targets above recent resistance — this supports momentum trading but also implies higher volatility. Moderna Price Forecast: Breakout Signals New Bull Trend
• Neutral Sentiment: Pipeline & operational updates: Norovirus Phase 3 is fully enrolled and other trials progressed; management also highlighted international manufacturing capacity — positive for long-term value but timeline-driven. Q4 press release / slide deck
• Negative Sentiment: Major regulatory setback: The U.S. FDA issued a refusal-to-file for Moderna’s new mRNA flu vaccine application, citing trial issues; Moderna has requested a Type A meeting, but the decision raises near-term uncertainty for one of its key pipeline catalysts and could pressure valuation. FDA refuses Moderna’s application for new mRNA flu vaccine
• Negative Sentiment: Volatility and mixed market reaction: Despite the beat, some outlets note the stock’s sharp pullback from the 52-week high and intraday swings after earnings — a sign investors are split between near-term optimism and longer-term execution/regulatory risks. Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings.

Insider Activity

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the sale, the director owned 3,924 shares in the company, valued at $115,679.52. This trade represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 10.90% of the company’s stock.

Hedge Funds Weigh In On Moderna

A number of large investors have recently modified their holdings of the company. Rothschild Investment LLC grew its position in Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after acquiring an additional 446 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of Moderna during the 2nd quarter valued at $26,000. Whittier Trust Co. purchased a new position in Moderna in the 2nd quarter worth $28,000. MUFG Securities EMEA plc bought a new stake in Moderna in the second quarter worth $28,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in Moderna during the fourth quarter valued at about $31,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.